Dubath, Céline http://orcid.org/0000-0002-6585-8492
Gholam-Rezaee, Mehdi
Sjaarda, Jennifer
Levier, Axel
Saigi-Morgui, Nuria
Delacrétaz, Aurélie
Glatard, Anaïs
Panczak, Radoslaw http://orcid.org/0000-0001-5141-683X
Correll, Christoph U.
Solida, Alessandra
Plessen, Kerstin Jessica
von Gunten, Armin
Kutalik, Zoltan
Conus, Philippe
Eap, Chin B. http://orcid.org/0000-0002-5439-0230
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (324730-144064, 320030-173211)
Article History
Received: 20 October 2020
Revised: 17 May 2021
Accepted: 7 June 2021
First Online: 26 June 2021
Change Date: 7 October 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41398-021-01520-6
Competing interests
: CE received honoraria for conferences or teaching CME courses from Janssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Vifor-Pharma, and Zeller in the past 3 years. AvG received honoraria for a conference or workshop participation from Vifor and Schwabe in the previous 3 years. Dr. Correll has been a consultant and/or advisor to or has received honoraria from: Alkermes, Allergan, Angelini, Gedeon Richter, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He has provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He received royalties from UpToDate and grant support from Janssen and Takeda. He is also a stock option holder of LB Pharma. The other authors declare no competing interests.